Page 6 - Jerome Lipper Multiple Myeloma Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kronos Bio Inc (KRON) Issues Pipeline Update and p300 KAT Inhibitor Development Candidate

Kronos Bio Inc (KRON) Issues Pipeline Update and p300 KAT Inhibitor Development Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kronos bioNikhilc munshiChristopher dinsmoreNorbert bischofbergerKronos bio incJerome lipper multiple myeloma centerDana farber cancer

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomChristopher dinsmoreJorge dimartinoNorbert bischofbergerKronos bioSarah connorsInhibitor developmentKronos bio incCorporate affairsCompany on linkedinBusiness developmentExchange commissionBio announces pipeline updateJerome lipper multiple myeloma centerDana farber cancerSan mateo

Oral CELMoD Mezigdomide May Address Logistical Challenges Linked With R/R Myeloma Management

Paul G. Richardson, MD, shares clinical findings and several case studies showcasing the encouraging activity and safety of mezigdomide in patients with relapsed/refractory multiple myeloma.

Dana farber cancer instituteUnited statesOmar nadimPaulg richardsonNizar bahlisClinical researchUniversity of calgaryMedicine at harvard medical schoolJerome lipper multiple myeloma centerCharbonneau cancer research instituteHarvard medical schoolCancer careNew england journalNorth americaActivity and safety of mezigdomide in patients with relapsed refractory multiple myelomaNovel celmod

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.

United statesPaulg richardsonChris ryanJerome lipper multiple myeloma centerDana farber cancer instituteHarvard medical schoolNew england journalApple podcastsGoogle podcastsAmazon musicMezigdomide and dexamethasonePatients with heavily pretreated relapsed refractory multiple myeloma

Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

Paulg richardsonHarvard medical schoolClinical researchDana farber cancer instituteJerome lipper multiple myeloma centerMultiple myelomaOnclive tvC 92480